Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy
Clinical trial NCT05806671 · UNKNOWN
Trial details
- NCT number
- NCT05806671
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-01
- Primary completion
- 2025-01-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.